抗人CD20和CD3 ε 双特异性参考抗体

Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody

货号：RB9T37014586

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37014586

中文名称
抗人CD20和CD3 ε 双特异性参考抗体

英文名称
Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody

形态
Liquid

纯度
>95% as determined by SDS-PAGE.

内毒素水平
Please contact with the lab for this information.

应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo

种属
Human

表达系统
Mammalian Cells

登录号
P11836 & P07766

宿主种属
Humanized

克隆性
Monoclonal

抗体亚型
IgG1-kappa-lambda

纯化方式
Protein A/G purified from cell culture supernatant.

浓度
1.06 mg/ml

种属反应性	靶标
Human	B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20, T3E, T-cell surface antigen T3/Leu-4

背景信息

Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as heathy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.

别名

Bispecific, CD20-TCB (2:1), RG-6026, 2229047-91-8

产品描述

Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab is an investigational, T-cell bispecific antibody with a distinctive design that features 2 Fab arms for binding CD20 on B cells, along with 1 Fab arm for binding CD3 on T cells. The CD3 binding arm is fused directly to one of the CD20-binding arms in a head-to-tail fashion via a short flexible linker.

储存缓冲液

0.01M PBS, pH 7.4.

稳定性和储存

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4° C short term (1-2 weeks). Store at -20° C 12 months. Store at -80° C long term.

For research use only. Not suitable for clinical or therapeutic use.